[go: up one dir, main page]

HK1257338A1 - 用於治療多發性骨髓瘤的btk抑制劑組合 - Google Patents

用於治療多發性骨髓瘤的btk抑制劑組合

Info

Publication number
HK1257338A1
HK1257338A1 HK18116541.0A HK18116541A HK1257338A1 HK 1257338 A1 HK1257338 A1 HK 1257338A1 HK 18116541 A HK18116541 A HK 18116541A HK 1257338 A1 HK1257338 A1 HK 1257338A1
Authority
HK
Hong Kong
Prior art keywords
multiple myeloma
btk inhibitor
treating multiple
inhibitor combinations
combinations
Prior art date
Application number
HK18116541.0A
Other languages
English (en)
Inventor
Elizabeth Bilotti
Thorsten Graef
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of HK1257338A1 publication Critical patent/HK1257338A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18116541.0A 2015-08-31 2018-12-24 用於治療多發性骨髓瘤的btk抑制劑組合 HK1257338A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562212518P 2015-08-31 2015-08-31
PCT/US2016/049638 WO2017040617A1 (en) 2015-08-31 2016-08-31 Btk inhibitor combinations for treating multiple myeloma

Publications (1)

Publication Number Publication Date
HK1257338A1 true HK1257338A1 (zh) 2019-10-18

Family

ID=56896818

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18115729.6A HK1256718A1 (zh) 2015-08-31 2018-12-07 用於治療多發性骨髓瘤的btk抑制劑組合
HK18116541.0A HK1257338A1 (zh) 2015-08-31 2018-12-24 用於治療多發性骨髓瘤的btk抑制劑組合

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18115729.6A HK1256718A1 (zh) 2015-08-31 2018-12-07 用於治療多發性骨髓瘤的btk抑制劑組合

Country Status (11)

Country Link
US (1) US20170209462A1 (zh)
EP (1) EP3344254A1 (zh)
JP (1) JP2018525411A (zh)
CN (1) CN108135904A (zh)
AU (1) AU2016317049A1 (zh)
BR (1) BR112018003836A2 (zh)
CA (1) CA2996177A1 (zh)
HK (2) HK1256718A1 (zh)
MA (1) MA45973A (zh)
MX (1) MX2018002554A (zh)
WO (1) WO2017040617A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5841998B2 (ja) 2010-06-03 2016-01-13 ファーマサイクリックス，インク． ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2019127008A1 (zh) * 2017-12-26 2019-07-04 清华大学 一种靶向降解btk的化合物及其应用
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
CN119097631A (zh) * 2019-12-03 2024-12-10 苏州亚盛药业有限公司 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
ATE195075T1 (de) 1991-11-22 2000-08-15 Procter & Gamble Pharma Risedronat enthaltende arzneimittel mit verzögerter wirkstoffabgabe
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
CA2147283C (en) 1992-10-16 2007-01-16 Kouichi Nakamichi Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0202461D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0202462D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
BRPI0414215A (pt) 2003-09-08 2006-11-07 Aventis Pharma Inc tienopirazóis
US20050176792A1 (en) 2004-01-14 2005-08-11 Boehringer Ingelheim Pharmaceuticals, Inc. Ketone substituted benzimidazole compounds
WO2005079791A1 (en) 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
CA2591413A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
WO2007016977A1 (de) 2005-08-05 2007-02-15 Delica Ag Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel
EP1919891B1 (en) 2005-08-29 2012-03-07 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
WO2007058832A2 (en) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
JP2009520831A (ja) 2005-12-20 2009-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｅｃキナーゼインヒビター
MX2008014450A (es) 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
HUE025459T2 (hu) 2006-09-22 2016-05-30 Pharmacyclics Inc A Bruton-féle tirozin-kináz inhibitorai
TWI475996B (zh) 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2011017219A1 (en) 2009-08-03 2011-02-10 The Regents Of The University Of California Imidazoquinoxalinones and anti-tumor treatment
JP5841998B2 (ja) * 2010-06-03 2016-01-13 ファーマサイクリックス，インク． ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
US9649313B2 (en) 2012-11-26 2017-05-16 The University Of North Carolina At Chapel Hill Use of ITK inhibitors for the treatment of cancer
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US9499519B2 (en) 2012-12-26 2016-11-22 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
EP2968332A4 (en) 2013-03-15 2016-08-03 Nantbioscience Inc SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2016161347A1 (en) * 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory

Also Published As

Publication number Publication date
AU2016317049A1 (en) 2018-03-15
EP3344254A1 (en) 2018-07-11
BR112018003836A2 (pt) 2018-12-04
MA45973A (fr) 2019-06-26
HK1256718A1 (zh) 2019-10-04
CN108135904A (zh) 2018-06-08
MX2018002554A (es) 2018-08-14
JP2018525411A (ja) 2018-09-06
US20170209462A1 (en) 2017-07-27
CA2996177A1 (en) 2017-03-09
WO2017040617A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
IL252504A0 (en) Synergistic use of cannabis to treat multiple myeloma
IL278247B (en) mct4 inhibitors to treat the disease
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1255871A1 (zh) 用於治療骨髓瘤的賽度替尼
HK1257338A1 (zh) 用於治療多發性骨髓瘤的btk抑制劑組合
HK1247607A1 (zh) P62-zz化學抑制劑
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
GB201513481D0 (en) Inhibitor compounds
GB201403536D0 (en) Inhibitor compounds
ZA201708386B (en) Treatment for multiple myeloma (mm)
GB201505658D0 (en) Inhibitor compounds
LT3164394T (lt) Gls1 inhibitoriai, skirti ligų gydymui
GB201501004D0 (en) Inhibitors
ZA201800638B (en) Fucosidase inhibitors
GB201502716D0 (en) Autotaxin inhibitors
IL256537A (en) Inhibitors for treating uveal melanoma
ZA201607068B (en) Methods for treating hypersomnia
PL3322724T3 (pl) Inhibitory IL-26
GB201520949D0 (en) Inhibitors
HK1257072A1 (zh) 治療多發性硬化的方法
GB201522453D0 (en) Inhibitor compounds
GB201621619D0 (en) Inhibitor compounds
GB201500644D0 (en) Inhibitor compounds